Dave Chenn News Today

Oceanpine Capital leads $73m funding in US biopharma firm Immune-Onc April 1, 2021 Immune-Onc Therapeutics, a California-based cancer immunotherapy firm co-founded by Chinese pharma specialist Charlene Liao, has raised $73 million in Series B1 and B2 rounds of financing, it announced earlier this week.   The latest funding brings the total capital raised by the company to $110 million, it said in a statement.  Beijing-headquartered Oceanpine Capital was the lead investor in the two rounds, wh...

Teon Therapeutics Completes $30 Million Series A Financing News provided by Share this article Share this article SAN FRANCISCO, Feb. 23, 2021 /PRNewswire/ -- Teon Therapeutics, a biopharmaceutical company developing small molecules that inhibit the immunosuppressive and cancer-promoting signaling pathways, today announced the completion of a $30M Series A financing. The financing was led by Oceanpine Capital with participation from additional new investors Oriza Ventures, Lifespan Investments...

China-focused growth equity investor Oceanpine closes DeepTech Fund at $400m Beijing, China. Source: Li Yang/Unsplash Premium Beijing-based growth equity investor Oceanpine Capital has held the final closing of its second US dollar fund, Oceanpine DeepTech Fund, at $400 million to make new bets on deeptech and innovative growth-stage companies in China’s TMT and biotech sectors. Continue reading this story with a subscription to DealStreetAsia. Contact us f...

Oceanpine Capital Hits $400Mn Final Close of Fund II In the time of unprecedented uncertainties, Oceanpine Capital Fund II successfully held its $400M final closing of Fund II as scheduled. Partnering with world-class entrepreneurs; investing in DeepTech arena and innovative growth companies in both TMT and Biotech sectors that are the driving force of the future economy in the New Norm. News provided by Share this article Share this article BEIJING, Dec. 28, 2020 /PRNewswire/ -- This is the fi...